Literature DB >> 24694551

Interactions between adrenal-regulatory and calcium-regulatory hormones in human health.

Jenifer M Brown1, Anand Vaidya.   

Abstract

PURPOSE OF REVIEW: To summarize the evidence characterizing the interactions between adrenal-regulating and calcium-regulating hormones, and the relevance of these interactions to human cardiovascular and skeletal health. RECENT
FINDINGS: Human studies support the regulation of parathyroid hormone (PTH) by the renin-angiotensin-aldosterone system (RAAS): angiotensin II may stimulate PTH secretion via an acute and direct mechanism, whereas aldosterone may exert a chronic stimulation of PTH secretion. Studies in primary aldosteronism, congestive heart failure, and chronic kidney disease have identified associations between hyperaldosteronism, hyperparathyroidism, and bone loss, which appear to improve when inhibiting the RAAS. Conversely, elevated PTH and insufficient vitamin D status have been associated with adverse cardiovascular outcomes, which may be mediated by the RAAS. Studies of primary hyperparathyroidism implicate PTH-mediated stimulation of the RAAS, and recent evidence shows that the vitamin D-vitamin D receptor complex may negatively regulate renin expression and RAAS activity. Ongoing human interventional studies are evaluating the influence of RAAS inhibition on PTH and the influence of vitamin D receptor agonists on RAAS activity.
SUMMARY: Although previously considered independent endocrine systems, emerging evidence supports a complex web of interactions between adrenal-regulating and calcium-regulating hormones, with implications for human cardiovascular and skeletal health.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24694551      PMCID: PMC4123208          DOI: 10.1097/MED.0000000000000062

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  88 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Bone loss in rats with aldosteronism.

Authors:  Aliye L Runyan; Vikram S Chhokar; Yao Sun; Syamal K Bhattacharya; John W Runyan; Karl T Weber
Journal:  Am J Med Sci       Date:  2005-07       Impact factor: 2.378

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery.

Authors:  G Bernini; A Moretti; S Lonzi; C Bendinelli; P Miccoli; A Salvetti
Journal:  Metabolism       Date:  1999-03       Impact factor: 8.694

5.  Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy.

Authors:  A Piovesan; N Molineri; F Casasso; I Emmolo; G Ugliengo; F Cesario; G Borretta
Journal:  Clin Endocrinol (Oxf)       Date:  1999-03       Impact factor: 3.478

6.  High parathyroid hormone, but not low vitamin D concentrations, expose elderly inpatients to hypertension.

Authors:  Leyla Mateus-Hamdan; Olivier Beauchet; Béatrice Bouvard; Erick Legrand; Bruno Fantino; Cédric Annweiler
Journal:  Geriatr Gerontol Int       Date:  2012-09-19       Impact factor: 2.730

7.  Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.

Authors:  Jenifer M Brown; Jonathan S Williams; James M Luther; Rajesh Garg; Amanda E Garza; Luminita H Pojoga; Daniel T Ruan; Gordon H Williams; Gail K Adler; Anand Vaidya
Journal:  Hypertension       Date:  2013-11-04       Impact factor: 10.190

8.  1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter.

Authors:  Weihua Yuan; Wei Pan; Juan Kong; Wei Zheng; Frances L Szeto; Kari E Wong; Ronald Cohen; Anna Klopot; Zhongyi Zhang; Yan Chun Li
Journal:  J Biol Chem       Date:  2007-08-09       Impact factor: 5.157

9.  Bone involvement in aldosteronism.

Authors:  Antonio Stefano Salcuni; Serena Palmieri; Vincenzo Carnevale; Valentina Morelli; Claudia Battista; Vito Guarnieri; Giuseppe Guglielmi; Gaetano Desina; Cristina Eller-Vainicher; Paolo Beck-Peccoz; Alfredo Scillitani; Iacopo Chiodini
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

10.  Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreas Tomaschitz; Astrid Fahrleitner-Pammer; Burkert Pieske; Nicolas Verheyen; Karin Amrein; Eberhard Ritz; Katharina Kienreich; Jörg H Horina; Albrecht Schmidt; Elisabeth Kraigher-Krainer; Caterina Colantonio; Andreas Meinitzer; Stefan Pilz
Journal:  BMC Endocr Disord       Date:  2012-09-13       Impact factor: 2.763

View more
  13 in total

1.  Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones.

Authors:  Omar Bayomy; Sarah Zaheer; Jonathan S Williams; Gary Curhan; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 2.  The renin-angiotensin-aldosterone system and calcium-regulatory hormones.

Authors:  A Vaidya; J M Brown; J S Williams
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

Review 3.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease.

Authors:  Katherine E Yutzey; Linda L Demer; Simon C Body; Gordon S Huggins; Dwight A Towler; Cecilia M Giachelli; Marion A Hofmann-Bowman; Douglas P Mortlock; Melissa B Rogers; Mehran M Sadeghi; Elena Aikawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-04       Impact factor: 8.311

4.  Postmenopausal osteoporosis is associated with elevated aldosterone/renin ratio.

Authors:  Xiaoyu Shu; Mei Mei; Linqiang Ma; Zhihong Wang; Shumin Yang; Jinbo Hu; Ying Song; Wenwen He; Ting Luo; Qingfeng Cheng; Yue Wang; Qianna Zhen; Qifu Li
Journal:  J Hum Hypertens       Date:  2018-05-22       Impact factor: 3.012

Review 5.  Adrenal disorders: Is there Any role for vitamin D?

Authors:  Giacomo Tirabassi; Gianmaria Salvio; Barbara Altieri; Cristina L Ronchi; Silvia Della Casa; Alfredo Pontecorvi; Giancarlo Balercia
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

6.  Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism.

Authors:  Anand Vaidya; Gary C Curhan; Julie M Paik; Henry Kronenberg; Eric N Taylor
Journal:  J Clin Endocrinol Metab       Date:  2015-04-17       Impact factor: 5.958

7.  Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.

Authors:  Jenifer Brown; Ian H de Boer; Cassianne Robinson-Cohen; David S Siscovick; Bryan Kestenbaum; Matthew Allison; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2014-11-20       Impact factor: 5.958

8.  Hyperparathyroidism in patients with overt and mild primary aldosteronism.

Authors:  Christos Gravvanis; Labrini Papanastasiou; Spiridoula Glycofridi; Nikos Voulgaris; Ernestini Tyfoxylou; Kounadi Theodora; George Piaditis; Αthina Markou
Journal:  Hormones (Athens)       Date:  2021-09-15       Impact factor: 2.885

9.  The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance.

Authors:  Nicolas Verheyen; Martin R Grübler; Cristiana Catena; Astrid Fahrleitner-Pammer; Adriana J van Ballegooijen
Journal:  Int J Endocrinol       Date:  2018-02-21       Impact factor: 3.257

Review 10.  Adrenal βarrestin1 targeting for tobacco-associated cardiac dysfunction treatment: Aldosterone production as the mechanistic link.

Authors:  Maria E Solesio; Erna Mitaishvili; Anastasios Lymperopoulos
Journal:  Pharmacol Res Perspect       Date:  2019-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.